• About Us
    • Corporate Profile
    • Global Footprint
    • Our Key Milestones
  • manufacturing
    • Infrastructure
    • Dosage Forms & Capacities
  • products & services
    • Products
    • Services
    • Join Hands With Naxpar
  • Investor relations
    • Financials
    • Shareholding Pattern
    • Shareholder Information
    • Investor Contact
  • Catalogues
    • Naxpar Specialities
    • Naxpar Generics
  • Contact Us
    • Contact Us
    • Adverse Event Reporting
QuarterlyResults


2022 – 2023

Quarter and 3 months ended
June, 2022
FinancialDownloadQuarter and 6 months ended September, 2022
FinancialDownload


2021 – 2022

Quarter ended
June 2021
FinancialDownloadQuarter & 6 Months ended
September 2021
FinancialDownloadQuarter and 9 Months ended
December, 2021
FinancialDownloadQuarter ended
March 2022
FinancialDownload


2020 – 2021

Quarter ended
June 2020
FinancialDownloadQuarter ended
September 2020
FinancialDownloadQuarter ended
December 2020
FinancialDownloadQuarter ended
March 2021
FinancialDownload

 


2019 – 2020

Quarter ended
June 2019
FinancialDownloadQuarter ended
September, 2019
Financial DownloadQuarter ended
December, 2019
Financial DownloadQuarter and Year ended
March, 2020
Financial Download
 


2018 – 2019

Quarter ended
June 2018
Financial DownloadQuarter and 6 months ended
September 2018
FinancialDownloadQuarter and 9 months ended
December 2018
FinancialDownloadQuarter and year ended
March 2019
FinancialDownload

 


2017 – 2018

Quarter ended
June 2017
FinancialDownloadQuarter and 6 months ended
September 2017
FinancialDownloadQuarter and 9 months ended
December 2017
FinancialDownloadQuarter and year ended
March 2018
FinancialDownload

 


2016 – 2017

Quarter ended
June 2016
FinancialDownload

Quarter and 6 months ended
September 2016
FinancialDownload

Quarter and 9 months ended
December 2016
FinancialDownload

Quarter and year ended
March 2017
FinancialDownload

Copyrights Reserved 2008-2022. Naxpar Group
en English
en Englishfr Frenchru Russianes Spanish